← All trials
NCT02002247
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Dec 1, 2019
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1400
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Clinical Evaluation Research Unit at Kingston General HospitalLead sponsor
- University of OttawaOverall official - principal investigator
- RWTH Aachen UniversityOverall official - principal investigator
- Queen's University, BelfastSponsor investigator
- RWTH Aachen UniversityCollaborator
- BiosynCollaborator
- Queen's University, BelfastOverall official - principal investigator
- Queen's University, BelfastCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.